The Danish Medicines Company not too long ago printed its annual medical hashish report, which particulars, amongst different issues, what number of medical hashish sufferers obtained prescriptions in Denmark in 2025, what number of whole prescriptions had been distributed, and what number of suspected adversarial reactions had been reported from the usage of authorized medical hashish merchandise.
“The report for 2025 exhibits solely three suspected adversarial response circumstances, no recognized alerts of latest or modified security dangers, and a big improve in the usage of medical hashish, with 22,410 prescriptions distributed to 2,465 sufferers.” the company said in a information launch.
“Following its evaluation of the reported circumstances, the Company concluded that no alerts of latest or modified security dangers had been recognized.” the information launch additionally said. “The report is printed as a part of the Danish Medicines Company’s ongoing monitoring of the protection and use of medical hashish in Denmark.”
Relating to the three reported adversarial response circumstances, “two of the three stories involved suspected critical adversarial reactions” and the opposite one “involved suspected non-serious adversarial reactions.” The Danish Medicines Company additionally famous that there have been “no suspected manufacturing quality-related adversarial reactions” recognized throughout the interval, and “the stories didn’t give rise to any extra danger mitigation measures.”
“The variety of adversarial response stories was unchanged from 2024, regardless of a big improve in the usage of medical hashish throughout 2025.” the company famous.
Danish sufferers had entry to 13 totally different medical hashish merchandise via the Danish Pilot Programme final yr. The 22,410 whole prescriptions distributed in 2025 had been a 64% improve in comparison with 2024. The variety of sufferers receiving prescriptions elevated by 54% in 2025 in comparison with 2024. The Danish Pilot Programme was first launched in 2018 and have become everlasting in the beginning of 2026.
“The annual report from the Danish Medicines Company gives vital details about the protection of medical hashish in Denmark. Regardless of a considerable improve within the variety of sufferers and prescriptions throughout 2025, solely three suspected adversarial response circumstances had been reported, and importantly, the Danish Medicines Company recognized no alerts of latest or modified security dangers.” said Thomas Skovlund Schnegelsberg, CEO of STENOCARE.
“The continued systematic monitoring by the Danish Medicines Company is vital for sufferers, physicians and the medical hashish sector. Within the annual report, the Company additionally considers that adversarial reactions may be underreported and can subsequently preserve concentrate on reminding physicians of their reporting obligations. This is a crucial a part of making certain continued and strong security monitoring.” he added.
“The truth that the report paperwork growing use provides helpful perspective on the extent of therapy in Denmark because the nation has now transitioned from the pilot programme to everlasting legalisation.” he concluded.
Sponsored Content
This informative article is brought to you by NUBO CBD →